Alprostadil - Endovasc

Drug Profile

Alprostadil - Endovasc

Alternative Names: Liprostin; PGE 1; Prostaglandin E1; PROStent

Latest Information Update: 12 Oct 2016

Price : $50

At a glance

  • Originator Endovasc; Liprostin Inc
  • Developer Endovasc; Endovasc-TissueGen Research Sponsors; Stentgenix
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E agonists; Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Peripheral vascular disorders
  • Discontinued Coronary artery restenosis; Diabetic neuropathies; Wounds

Most Recent Events

  • 12 Oct 2016 AngioSoma files for three patent applications for alprostadil in USA
  • 14 Jul 2016 Phase-II clinical trials in Peripheral vascular disorders in USA (Parenteral)
  • 14 Jul 2016 AngioSoma plans a phase III trial for Peripheral Vascular disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top